Group One Trading
CTKB icon

Group One Trading’s Cytek Biosciences CTKB Stock Holding History

Group One Trading’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-700
Closed -$3.86K – 7511
2023
Q3 		$3.86K Buy
700
+500
+250% +$4.01K ﹤0.01% 6818
2023
Q2 		$1.71K Buy
+200
New +$1.79K ﹤0.01% 7127

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Group One Trading's CTKB Position: Q2 2026 in Review

Group One Trading reduced its Cytek Biosciences (CTKB) stake by 89% in Q2 2026, selling an estimated $8.32K and leaving 250 shares worth $1.11K. The position accounts for ﹤0.01% of the portfolio, ranked #7163.

Group One Trading first reported a position in CTKB in Q4 2022 and has held it in 6 quarters since. The position peaked at $68.3K in Q4 2023. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Group One Trading held 250 shares of Cytek Biosciences worth $1.11K as of Q2 2026.
  • Group One Trading sold 1,950 Cytek Biosciences shares in Q2 2026, an estimated $8.32K.
  • Cytek Biosciences made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #7163 holding.
  • Group One Trading first reported a position in Cytek Biosciences in Q4 2022 and has held it in 6 quarters since.
  • Group One Trading's Cytek Biosciences position peaked at $68.3K in Q4 2023.
  • 154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.